<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486990</url>
  </required_header>
  <id_info>
    <org_study_id>TGLIA-5.001</org_study_id>
    <nct_id>NCT03486990</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease</brief_title>
  <official_title>A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>COUR Pharmaceutical Development Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to characterize the safety and tolerability of an investigational drug called
      TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease.
      The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and
      urine, and study subject health will also be monitored by vital signs such as blood pressure,
      electrocardiogram (ECG), and physical examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 2-part, multicenter study. In Part A, eligible subjects will be enrolled into
      escalating dose cohorts (n = 2/cohort for 2 dose levels followed by n = 3/cohort for 4 dose
      levels). TIMP-GLIA will be administered as a single intravenous (IV) infusion on Day 1. A
      staggered dosing strategy will be used in Part A. Subjects will undergo medical observation
      in the clinic for at least 48 hours after dosing and participate in outpatient follow-up
      visits. Adverse events (AEs), vital signs, and electrocardiograms (ECGs) and laboratory data
      (serum chemistry, coagulation, hematology and urinalysis, cytokines) will be assessed by a
      Safety Committee before the next cohort will be dosed at a higher dose level.

      After completion of Part A and confirmation by the Safety Committee to proceed, eligible
      subjects (n=3) will receive two IV infusions of TIMP-GLIA, 7 days apart, on Day 1 and on Day
      8. Each subject in Part B will be observed in clinic for 48 hours after each dose and undergo
      similar testing and follow-up visits as in Part A.

      The safety and pharmacokinetic profile of TIMP-GLIA will be characterized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single ascending dose followed by repeat dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 up to Day 180</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse Events</measure>
    <time_frame>From Day 1 up to Day 180</time_frame>
    <description>AE Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.0. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE. Drug-related adverse events are those that the investigator assessed as possibly or probably related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Findings</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiograms (ECG) Findings</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation Levels</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 3</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 7</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 8</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 10</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 14</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 38</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 60</time_frame>
    <description>Baseline is defined as Day 1 pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1</measure>
    <time_frame>Baseline (Day 1 pre-dose) and 15 minutes (min) post-dose on Day 1</time_frame>
    <description>Baseline was defined as Day 1 Pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1</measure>
    <time_frame>Baseline (Day 1 pre-dose) and 30 min post-dose on Day 1</time_frame>
    <description>Baseline was defined as Day 1 Pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 2</time_frame>
    <description>Baseline was defined as Day 1 Pre-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and Urinalysis</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A (Greater Than or Equal to [&gt;=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release Markers</measure>
    <time_frame>Part A (&gt;=4.0 mg/kg): Day 1 pre-dose up to 144 hours post-dose on Day 7; Part B: Day 8 pre-dose up to 144 hours post-dose on Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>From Day 1 up to Day 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration For TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast: Last Measurable Observed Plasma Concentration For TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast: Time to Reach the Last Measurable Plasma Concentration for TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Terminal Phase Elimination Half-life (T1/2) for TIMP-GLIA</measure>
    <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Part A, Cohort 1: 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 2: 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 3: 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 4: 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 5: 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 6: 8.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 1: 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 2: 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 3: 8.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIMP-GLIA</intervention_name>
    <description>intravenous infusion.</description>
    <arm_group_label>Part A, Cohort 1: 0.1 mg/kg</arm_group_label>
    <arm_group_label>Part A, Cohort 2: 0.5 mg/kg</arm_group_label>
    <arm_group_label>Part A, Cohort 3: 1.0 mg/kg</arm_group_label>
    <arm_group_label>Part A, Cohort 4: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part A, Cohort 5: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part A, Cohort 6: 8.0 mg/kg</arm_group_label>
    <arm_group_label>Part B, Cohort 1: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part B, Cohort 2: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part B, Cohort 3: 8.0 mg/kg</arm_group_label>
    <other_name>TAK-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject provides written informed consent and is willing and able to comply with
             study requirements.

          -  At screening the subject has a minimum body mass index (BMI) of 16 kg/m2 and a minimum
             body weight of 33 kg up to a maximum body weight of 129 kg, inclusive. If subject is
             considered to be underweight or overweight/obese, the subject is otherwise healthy in
             the opinion of the investigator.

          -  The subject has celiac disease characterized at Screening Visit by:

          -  a history of biopsy-confirmed celiac disease; and

          -  no known gluten exposure for at least 10 days; and

          -  willingness to maintain a gluten-free diet for the duration of the study; and

          -  a negative or weak positive transglutaminase (tTG)-specific IgA titer if the subject
             has a normal total immunoglobulin A (IgA) titer or has a partial IgA deficiency OR

          -  a negative or weak positive deamidated gliadin peptide (DGP)-specific immunoglobulin G
             (IgG) titer if the subject has IgA deficiency.

          -  The male subject or female subject of childbearing potential will practice medically
             approved contraception during the study.

        Exclusion Criteria:

          -  The subject has a history of clinically confirmed immunoglobulin E-mediated reaction
             and/or anaphylaxis to wheat (i.e., &quot;wheat allergy&quot;), barley or rye.

          -  The subject has a known history of hypersensitivity or allergies to TIMP-GLIA
             components OR any other known severe hypersensitivity or allergic reaction (resulted
             in hospitalization [initial or prolonged], congenital anomaly, or disability, or that
             required medical intervention to prevent permanent impairment or damage) to any other
             allergens (medications, food or environmental).

          -  The subject has uncontrolled celiac disease and/or complications of celiac disease, or
             otherwise has experienced celiac symptomology within 10 days of screening, in the
             opinion of the investigator.

          -  The subject has a history of, or has an active, significant, clinically relevant,
             comorbidity (including Type 1 and Type 2 diabetes mellitus and other autoimmune
             disorders, splenectomy) that, in the opinion of the investigator, would make the
             subject unsuitable for participation in the study and/or could adversely affect
             interpretation of the study results.

          -  The subject has had significant changes to or anticipates changes to prescription or
             non-prescription medication used to manage an underlying comorbidity within 30 days
             prior to first dosing (Day 1).

          -  The subject is currently taking or received systemic biologics 6 months prior to first
             dosing (Day 1).

          -  The subject has a compromised immune system, e.g.

          -  known human immunodeficiency virus (HIV) infection or positive for HIV antibodies at
             Screening or

          -  immunosuppressive medical treatment taken during the 2 months prior to first dosing
             (Day 1) or

          -  immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily
             for 2 weeks or more within 2 months prior to first dosing (Day 1), or any dose of
             corticosteroids within 30 days of first dosing (Day 1), or high dose inhaled
             corticosteroids [&gt;960 µg/day of beclomethasone dipropionate or equivalent]) within 30
             days of first dosing Day 1.

          -  The subject has currently untreated or active gastrointestinal disease such as peptic
             ulcer disease, esophagitis (Los Angeles Classification ≥ Grade C), irritable bowel
             syndrome, inflammatory bowel disease, or microscopic colitis.

          -  The subject has an active malignancy, or history of malignancy or chemotherapy, within
             the past 5 years other than history of localized or surgical removal of focal basal
             cell skin cancer, cervical cancer in situ treated successfully in the past by local
             treatment (including but not limited to cryotherapy or laser therapy) or by
             hysterectomy.

          -  The subject has known liver disease or serology positive for hepatitis C infection;
             positive hepatitis B surface antigen (HBsAg) at Screening Visit.

          -  The subject has a positive test result for drugs of abuse, cannabinoids, or alcohol at
             Screening Visit or at Check-in.

          -  The subject has a history of any drug or alcohol abuse in the past 5 years or alcohol
             consumption habits that, in the opinion of the investigator, would interfere with the
             subject's ability to comply with the study requirements.

          -  The subject has clinically significant laboratory test results (e.g., liver tests) or
             electrocardiogram (EGC) abnormalities (e.g., cardiac conduction abnormalities) at
             Screening

          -  The subject received a live or inactive vaccine within 28 days prior or a subunit
             vaccine within 14 days prior to first dosing/Day 1 or the subject has a planned
             vaccination during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacksonville Center For Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital Translational and Clinical Research Centers</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Gastroenterology Research Unit</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>celiac</keyword>
  <keyword>gliadin</keyword>
  <keyword>gluten</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03486990/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03486990/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 5 investigative sites in the United States from 23 January 2018 to 22 July 2019.</recruitment_details>
      <pre_assignment_details>Participants diagnosed with celiac disease (CD) were enrolled to receive TIMP-GLIA as a single dose escalation of 0.1 milligram per kilogram (mg/kg), 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, 8.0 mg/kg in Part A; and TIMP-GLIA as a two dose escalation of 2.0 mg/kg, 4.0 mg/kg, 8.0 mg/kg in Part B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A, Cohort 1: 0.1 mg/kg</title>
          <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part A, Cohort 2: 0.5 mg/kg</title>
          <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part A, Cohort 3: 1.0 mg/kg</title>
          <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part A, Cohort 4: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part A, Cohort 5: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part A, Cohort 6: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part B, Cohort 1: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="P8">
          <title>Part B, Cohort 2: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="P9">
          <title>Part B, Cohort 3: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A, Cohort 1: 0.1 mg/kg</title>
          <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part A, Cohort 2: 0.5 mg/kg</title>
          <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part A, Cohort 3: 1.0 mg/kg</title>
          <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part A, Cohort 4: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part A, Cohort 5: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part A, Cohort 6: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part B, Cohort 1: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="B8">
          <title>Part B, Cohort 2: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="B9">
          <title>Part B, Cohort 3: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="27.58"/>
                    <measurement group_id="B2" value="53.5" spread="20.51"/>
                    <measurement group_id="B3" value="39.3" spread="15.57"/>
                    <measurement group_id="B4" value="38.0" spread="4.58"/>
                    <measurement group_id="B5" value="48.3" spread="14.19"/>
                    <measurement group_id="B6" value="27.5" spread="4.65"/>
                    <measurement group_id="B7" value="42.5" spread="13.44"/>
                    <measurement group_id="B8" value="53.5" spread="7.78"/>
                    <measurement group_id="B9" value="32.5" spread="2.12"/>
                    <measurement group_id="B10" value="40.3" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>From Day 1 up to Day 180</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse Events</title>
        <description>AE Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.0. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE. Drug-related adverse events are those that the investigator assessed as possibly or probably related to the study treatment.</description>
        <time_frame>From Day 1 up to Day 180</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse Events</title>
          <description>AE Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.0. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE. Drug-related adverse events are those that the investigator assessed as possibly or probably related to the study treatment.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or Higher TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Electrocardiograms (ECG) Findings</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiograms (ECG) Findings</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation Levels</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation Levels</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 3</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>units per milliliter (U/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.000"/>
                    <measurement group_id="O2" value="0.60" spread="0.141"/>
                    <measurement group_id="O3" value="-0.35" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 7</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.071"/>
                    <measurement group_id="O2" value="0.00" spread="0.000"/>
                    <measurement group_id="O3" value="0.85" spread="1.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 8</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA. The safety analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA. The safety analysis population where data at specified time points were available.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.141"/>
                    <measurement group_id="O2" value="0.10" spread="NA">Standard deviation could not be calculated since only 1 participant was available for analysis.</measurement>
                    <measurement group_id="O3" value="1.50" spread="1.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 10</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.778"/>
                    <measurement group_id="O2" value="1.00" spread="1.273"/>
                    <measurement group_id="O3" value="1.25" spread="1.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 14</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.141"/>
                    <measurement group_id="O2" value="1.65" spread="0.495"/>
                    <measurement group_id="O3" value="1.30" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 38</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA. The safety analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA. The safety analysis population where data at specified time points were available.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="NA">Standard deviation could not be calculated since only 1 participant was available for analysis.</measurement>
                    <measurement group_id="O2" value="1.50" spread="1.273"/>
                    <measurement group_id="O3" value="1.00" spread="1.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60</title>
        <description>Baseline is defined as Day 1 pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60</title>
          <description>Baseline is defined as Day 1 pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.495"/>
                    <measurement group_id="O2" value="2.85" spread="0.778"/>
                    <measurement group_id="O3" value="3.30" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.354"/>
                    <measurement group_id="O2" value="1.15" spread="1.061"/>
                    <measurement group_id="O3" value="1.10" spread="1.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1</title>
        <description>Baseline was defined as Day 1 Pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and 15 minutes (min) post-dose on Day 1</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1</title>
          <description>Baseline was defined as Day 1 Pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose): C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.25" spread="23.264"/>
                    <measurement group_id="O2" value="16.15" spread="0.636"/>
                    <measurement group_id="O3" value="18.65" spread="17.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 15 min post-dose on Day 1: C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.40" spread="43.841"/>
                    <measurement group_id="O2" value="134.90" spread="104.369"/>
                    <measurement group_id="O3" value="46.25" spread="13.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Day 1 pre-dose): SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.5" spread="17.68"/>
                    <measurement group_id="O2" value="95.5" spread="33.23"/>
                    <measurement group_id="O3" value="112.0" spread="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 15 min post-dose on Day 1: SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="49.50"/>
                    <measurement group_id="O2" value="196.0" spread="193.75"/>
                    <measurement group_id="O3" value="130.5" spread="33.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1</title>
        <description>Baseline was defined as Day 1 Pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and 30 min post-dose on Day 1</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1</title>
          <description>Baseline was defined as Day 1 Pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose): C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.25" spread="23.264"/>
                    <measurement group_id="O2" value="16.15" spread="0.636"/>
                    <measurement group_id="O3" value="18.65" spread="17.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 30 min post-dose on Day 1: C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" spread="56.569"/>
                    <measurement group_id="O2" value="144.00" spread="11.455"/>
                    <measurement group_id="O3" value="65.65" spread="34.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Day 1 pre-dose): SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.5" spread="17.68"/>
                    <measurement group_id="O2" value="95.5" spread="33.23"/>
                    <measurement group_id="O3" value="112.0" spread="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 30 min post-dose on Day 1: SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.0" spread="2.83"/>
                    <measurement group_id="O2" value="307.0" spread="41.01"/>
                    <measurement group_id="O3" value="293.0" spread="185.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2</title>
        <description>Baseline was defined as Day 1 Pre-dose.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 2</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2</title>
          <description>Baseline was defined as Day 1 Pre-dose.</description>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1 pre-dose): C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.25" spread="23.264"/>
                    <measurement group_id="O2" value="16.15" spread="0.636"/>
                    <measurement group_id="O3" value="18.65" spread="17.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2: C3a level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.55" spread="12.092"/>
                    <measurement group_id="O2" value="0.90" spread="0.990"/>
                    <measurement group_id="O3" value="-6.70" spread="20.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Day 1 pre-dose): SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.5" spread="17.68"/>
                    <measurement group_id="O2" value="95.5" spread="33.23"/>
                    <measurement group_id="O3" value="112.0" spread="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2: SC5B-9 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="14.14"/>
                    <measurement group_id="O2" value="-12.5" spread="36.06"/>
                    <measurement group_id="O3" value="2.0" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and Urinalysis</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and Urinalysis</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A (Greater Than or Equal to [&gt;=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release Markers</title>
        <time_frame>Part A (&gt;=4.0 mg/kg): Day 1 pre-dose up to 144 hours post-dose on Day 7; Part B: Day 8 pre-dose up to 144 hours post-dose on Day 14</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O4">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O5">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A (Greater Than or Equal to [&gt;=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release Markers</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
        <time_frame>From Day 1 up to Day 60</time_frame>
        <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 1: 0.1 mg/kg</title>
            <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O9">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
          <population>The safety population, included all participants who signed the study-specific informed consent document and received at least 1 dose of TIMP-GLIA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration For TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration For TIMP-GLIA</title>
          <population>The pharmacokinetic (PK) population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" spread="48.4"/>
                    <measurement group_id="O2" value="220" spread="3.0"/>
                    <measurement group_id="O3" value="457" spread="17.6"/>
                    <measurement group_id="O4" value="845" spread="23.6"/>
                    <measurement group_id="O6" value="252" spread="6.7"/>
                    <measurement group_id="O7" value="529" spread="22.6"/>
                    <measurement group_id="O8" value="938" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="NA" spread="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or Percent of area under the plasma concentration-time curve extrapolated to infinity (%AUCextrap) exceeds 25%.</measurement>
                    <measurement group_id="O7" value="408" spread="26.8"/>
                    <measurement group_id="O8" value="735" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clast: Last Measurable Observed Plasma Concentration For TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Clast: Last Measurable Observed Plasma Concentration For TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="12.2"/>
                    <measurement group_id="O2" value="63.9" spread="29.2"/>
                    <measurement group_id="O3" value="68.6" spread="27.2"/>
                    <measurement group_id="O4" value="55.8" spread="30.2"/>
                    <measurement group_id="O5" value="77.2" spread="23.7"/>
                    <measurement group_id="O6" value="97.9" spread="85.1"/>
                    <measurement group_id="O7" value="47.9" spread="19.0"/>
                    <measurement group_id="O8" value="111" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="NA" spread="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="133" spread="137.7"/>
                    <measurement group_id="O8" value="54.4" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.50" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.50" upper_limit="0.58"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.50" upper_limit="0.58"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.50" upper_limit="0.58"/>
                    <measurement group_id="O6" value="2.86" lower_limit="2.85" upper_limit="2.87"/>
                    <measurement group_id="O7" value="3.21" lower_limit="2.82" upper_limit="3.60"/>
                    <measurement group_id="O8" value="2.94" lower_limit="2.83" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="3.08" lower_limit="2.82" upper_limit="3.33"/>
                    <measurement group_id="O8" value="2.90" lower_limit="2.80" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="604" spread="3.4"/>
                    <measurement group_id="O3" value="3100" spread="27.0"/>
                    <measurement group_id="O4" value="3170" spread="22.8"/>
                    <measurement group_id="O5" value="8430" spread="48.9"/>
                    <measurement group_id="O6" value="NA" spread="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="3220" spread="31.5"/>
                    <measurement group_id="O8" value="5080" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="NA" spread="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O8" value="3250" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="210.7"/>
                    <measurement group_id="O2" value="503" spread="12.1"/>
                    <measurement group_id="O3" value="1690" spread="88.1"/>
                    <measurement group_id="O4" value="2920" spread="21.6"/>
                    <measurement group_id="O5" value="2870" spread="501.3"/>
                    <measurement group_id="O6" value="932" spread="65.2"/>
                    <measurement group_id="O7" value="2930" spread="30.6"/>
                    <measurement group_id="O8" value="4590" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="NA" spread="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="1410" spread="107.1"/>
                    <measurement group_id="O8" value="3050" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast: Time to Reach the Last Measurable Plasma Concentration for TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast: Time to Reach the Last Measurable Plasma Concentration for TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" lower_limit="1.00" upper_limit="3.98"/>
                    <measurement group_id="O2" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="12.17" lower_limit="4.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="12.00" lower_limit="12.00" upper_limit="12.17"/>
                    <measurement group_id="O5" value="12.00" lower_limit="4.02" upper_limit="24.53"/>
                    <measurement group_id="O6" value="7.99" lower_limit="4.00" upper_limit="11.98"/>
                    <measurement group_id="O7" value="18.10" lower_limit="12.20" upper_limit="24.00"/>
                    <measurement group_id="O8" value="12.00" lower_limit="12.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="8.01" lower_limit="4.02" upper_limit="12.00"/>
                    <measurement group_id="O8" value="12.08" lower_limit="12.00" upper_limit="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2: Terminal Phase Elimination Half-life (T1/2) for TIMP-GLIA</title>
        <time_frame>Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose</time_frame>
        <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, Cohort 2: 0.5 mg/kg</title>
            <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A, Cohort 3: 1.0 mg/kg</title>
            <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A, Cohort 4: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A, Cohort 5: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A, Cohort 6: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part B, Cohort 1: 2.0 mg/kg</title>
            <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O7">
            <title>Part B, Cohort 2: 4.0 mg/kg</title>
            <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
          <group group_id="O8">
            <title>Part B, Cohort 3: 8.0 mg/kg</title>
            <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2: Terminal Phase Elimination Half-life (T1/2) for TIMP-GLIA</title>
          <population>The PK population who received at least 1 dose of TIMP-GLIA and had at least 1 PK parameter reported. The PK analysis population where data at specified time points were available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was not calculated in more than 1/3 of participants due to poor or incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O2" value="1.81" lower_limit="1.63" upper_limit="2.57"/>
                    <measurement group_id="O3" value="4.38" lower_limit="1.92" upper_limit="8.24"/>
                    <measurement group_id="O4" value="3.03" lower_limit="2.86" upper_limit="3.35"/>
                    <measurement group_id="O5" value="4.36" lower_limit="2.72" upper_limit="6.00"/>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Parameter was not estimable in more than 1/3 of participants due to poor/incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O7" value="4.60" lower_limit="2.77" upper_limit="6.43"/>
                    <measurement group_id="O8" value="3.03" lower_limit="3.02" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Parameter was not estimable in more than 1/3 of participants due to poor/incomplete profile and not estimable in WinNonLin, or %AUCextrap exceeds 25%.</measurement>
                    <measurement group_id="O8" value="2.51" lower_limit="2.46" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs are adverse events that started after the first dose of study drug up to Day 180</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A, Cohort 1: 0.1 mg/kg</title>
          <description>TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part A, Cohort 2: 0.5 mg/kg</title>
          <description>TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part A, Cohort 3: 1.0 mg/kg</title>
          <description>TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part A, Cohort 4: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part A, Cohort 5: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part A, Cohort 6: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part B, Cohort 1: 2.0 mg/kg</title>
          <description>TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="E8">
          <title>Part B, Cohort 2: 4.0 mg/kg</title>
          <description>TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
        <group group_id="E9">
          <title>Part B, Cohort 3: 8.0 mg/kg</title>
          <description>TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tongue geographic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Medical device site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gluten sensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

